百利天恒：双抗ADC治疗肺癌研究结果显著 客观缓解率达100%

Core Viewpoint - Baili Tianheng's self-developed drug, iza-bren, has shown promising results in treating EGFR-mutant lung cancer, as presented at the 2025 World Lung Cancer Conference (WCLC) [1] Group 1: Research Results - The Phase II study of iza-bren combined with Osimertinib for first-line treatment of EGFR-mutant NSCLC reported an objective response rate (ORR) of 100% among 40 patients receiving a 2.5 mg/kg dose [1] - The 12-month progression-free survival (PFS) rate was 92.1%, and the overall survival (OS) rate reached 94.8% [1] - All patients exhibited a reduction in target lesions, indicating effective treatment [1]